Form 6-K BioLineRx Ltd. For: Aug 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Roth Capital Positive on BioLineRx (BLRX) Following BL-8040 Phase 2b Initiation
August 17, 2015 9:48 AM UTCRoth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target after the company announced the initiation of a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML).
Analyst Joseph Pantginis noted, This study is an important first step in the development of BL-8040 and the planned broadening of its profile, in our belief. The rationale for this study comes from... More
